Clinical trial
A Prospective, Randomized Controlled Study of Perioperative Disitamab Vedotin Plus Immunotherapy Versus Chemotherapy Plus Immunotherapy in Patients With Resectable HER2-Expressing Muscle-Invasive Bladder Cancer (HOPE-07-MIBC Study)
NCT07608224 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Randomized Controlled Study of Perioperative Disitamab Vedotin Plus Immunotherapy Versus Chemotherapy Plus Immunotherapy in Patients With Resectable HER2-Expressing Muscle-Invasive Bladder Cancer (HOPE-07-MIBC Study)
- Lead sponsor
- West China Hospital
- Phase
- Phase 2/3
- Overall status
- Not yet recruiting
- Start date
- June 20, 2026
- Completion date
- December 31, 2030
- Enrollment
- 240 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.